• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Rigel to Present at the Jefferies Global Healthcare Conference

    5/28/25 8:05:00 AM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RIGL alert in real time by email

    SOUTH SAN FRANCISCO, Calif., May 28, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 12:50 p.m. ET in New York, NY.

    To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.

    About Rigel

    Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

    Contact for Investors & Media:

    Investors: 

    Rigel Pharmaceuticals, Inc. 

    650.624.1232 

    [email protected]

    Media:

    David Rosen 

    Argot Partners 

    646.461.6387

    [email protected] 

    Rigel Pharmaceuticals Logo (PRNewsfoto/Rigel Pharmaceuticals, Inc.)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-jefferies-global-healthcare-conference-302466594.html

    SOURCE Rigel Pharmaceuticals, Inc.

    Get the next $RIGL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RIGL

    DatePrice TargetRatingAnalyst
    11/5/2025$42.00Hold → Buy
    Jefferies
    4/3/2023$2.00Neutral
    Piper Sandler
    6/9/2022Buy → Neutral
    Citigroup
    6/8/2022$7.00 → $1.00Overweight → Neutral
    Piper Sandler
    6/8/2022$6.00 → $1.00Overweight → Neutral
    Cantor Fitzgerald
    3/23/2022$4.00Neutral
    B. Riley Securities
    More analyst ratings

    $RIGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by EVP & Chief Financial Officer Schorno Dean L

    4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)

    9/17/25 4:27:04 PM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, Chief Commercial Officer Santos David A

    4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)

    9/17/25 4:26:54 PM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, Chief Medical Officer Rojkjaer Lisa

    4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)

    9/17/25 4:26:41 PM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RIGL
    SEC Filings

    View All

    Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)

    11/4/25 4:11:38 PM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Rigel Pharmaceuticals Inc.

    10-Q - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)

    11/4/25 4:06:41 PM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Rigel Pharmaceuticals Inc.

    SCHEDULE 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

    10/7/25 4:15:56 PM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RIGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rigel Pharma upgraded by Jefferies with a new price target

    Jefferies upgraded Rigel Pharma from Hold to Buy and set a new price target of $42.00

    11/5/25 3:49:31 PM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler resumed coverage on Rigel Pharma with a new price target

    Piper Sandler resumed coverage of Rigel Pharma with a rating of Neutral and set a new price target of $2.00

    4/3/23 9:11:21 AM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rigel Pharma downgraded by Citigroup

    Citigroup downgraded Rigel Pharma from Buy to Neutral

    6/9/22 7:22:28 AM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RIGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

    Third quarter 2025 total revenue of approximately $69.5 million, including record net product sales of $64.1 million and contract revenues from collaborations of $5.4 million Generated $27.9 million of net income in the third quarter of 2025Completed enrollment in the dose escalation phase and enrolled the first patient in the dose expansion phase of the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in lower-risk MDS Oral presentation featuring updated data from the dose escalation phase of the R289 Phase 1b study to be presented at the ASH Annual Meeting in DecemberUpdated 2025 Outlook: Total revenue of approximately $285 to $290 million, which includes net product

    11/4/25 4:01:00 PM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition

    Oral presentation to feature updated data from the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients with relapsed or refractory lower-risk MDS Four poster presentations will exhibit new REZLIDHIA® (olutasidenib) data in patients with R/R mIDH1 AMLSOUTH SAN FRANCISCO, Calif., Nov. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b study of R2891, a potent and selective inhibitor of dual interleukin receptor-associated kinases 1 and 4 (IRAK1/4), in patients with lower-risk myelodysplastic syndrome (MDS) who

    11/3/25 9:05:00 AM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update

    SOUTH SAN FRANCISCO, Calif., Oct. 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its third quarter 2025 financial results after market close on Tuesday, November 4, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business. Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's

    10/29/25 8:05:00 AM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RIGL
    Financials

    Live finance-specific insights

    View All

    Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

    Third quarter 2025 total revenue of approximately $69.5 million, including record net product sales of $64.1 million and contract revenues from collaborations of $5.4 million Generated $27.9 million of net income in the third quarter of 2025Completed enrollment in the dose escalation phase and enrolled the first patient in the dose expansion phase of the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in lower-risk MDS Oral presentation featuring updated data from the dose escalation phase of the R289 Phase 1b study to be presented at the ASH Annual Meeting in DecemberUpdated 2025 Outlook: Total revenue of approximately $285 to $290 million, which includes net product

    11/4/25 4:01:00 PM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update

    SOUTH SAN FRANCISCO, Calif., Oct. 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its third quarter 2025 financial results after market close on Tuesday, November 4, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business. Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's

    10/29/25 8:05:00 AM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update

    Second quarter 2025 total revenue of approximately $101.7 million, which includes net product sales of $58.9 million and contract revenues from collaborations of $42.7 million Completed enrollment in the dose escalation part of the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in patients with R/R lower-risk MDSGenerated $59.6 million of net income in the second quarter of 2025Updated 2025 Outlook: Total revenue of approximately $270 to $280 million, which includes net product sales of $210 to $220 millionTotal revenue and net income are inclusive of $40 million in non-cash contract revenue related to Rigel's agreement with LillyConference call and webcast scheduled today

    8/5/25 4:01:00 PM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RIGL
    Leadership Updates

    Live Leadership Updates

    View All

    Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

    SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical oncologist and brings more than 25 years of experience developing cellular immunotherapies to treat cancer, including deep expertise in clinical drug development and translational research, and portfolio strategy.   "We are pleased to have Mark join our Board," said Raul Rodriguez, Rigel's president and CEO. "His experience in clinical development, translational research and portfolio strategy will be a valuable addition to Rigel as we advance our hematology and oncology developm

    3/10/25 8:05:00 AM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology. She is a board-certified hematologist with an international clinical practice background. "It is a pleasure to welcome Lisa to the team. She brings to Rigel a strong combination of industry leadership experience paired with drug development and regulatory affairs expertise. Her robust hematology and oncology knowledge comp

    3/12/24 8:05:00 AM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

    STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company's financial operations. "Ryan's deep financial leadership experience will be instrumental to the execution of Cara's long-term growth strategy as we continue to maximize the KORSUVA™ (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position

    9/12/22 7:00:00 AM ET
    $CARA
    $IOVA
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $RIGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Rigel Pharmaceuticals Inc.

    SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

    11/14/24 5:18:08 PM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rigel Pharmaceuticals Inc.

    SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

    11/14/24 3:33:13 PM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Rigel Pharmaceuticals Inc.

    SC 13G - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

    11/8/24 9:33:38 AM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care